Spago Nanomedical strengthened management to reflect project progress

The clinical phase I/IIa study evaluating radiopharmaceutical candidate 177Lu-SN201 in solid tumours has been progressing steadily for Spago Nanomedical.

This progress has led the company to put more focus on regulatory priorities. As part of this, the company recently strengthened its management team by adding Birgitta Rembratt Svensson as Head of CMC and Supply.